Glaukos has received a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa, a corneal cross-linking therapy for keratoconus patients. The new code, J2789, was assigned by the U.S. Centers for Medicare and Medicaid Services (CMS) and is set to take effect July 1, 2026.
J-codes are used by healthcare providers and payers to standardize billing and reimbursement for physician-administered pharmaceuticals. According to Glaukos, this product-specific J-code is expected to enable a simplified claims processing and support more consistent coverage decisions across both government and commercial payers.
“The assignment of a product-specific J-code for Epioxa represents an important milestone, supporting our market access initiatives to increase access and expand coverage for patients suffering from keratoconus,” says Thomas Burns, Glaukos chairman and chief executive officer. “Once effective, this new J-code is expected to enable more streamlined and consistent coverage and payment for Epioxa over time, strengthening the foundation for our commercial launch and enabling broader patient access.”
About Epioxa
Epioxa is an epithelium-on, incision-free corneal cross-linking therapy for keratoconus. The oxygen-enriched topical treatment is activated by UV light and does not require removal of the corneal epithelium, the outermost layer of the front of the eye. This is intended to reduce patient discomfort and recovery time, the company says.
Epioxa HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and Epioxa (riboflavin 5’-phosphate ophthalmic solution) 0.177% are indicated for use in corneal collagen cross-linking in patients aged 13 and older. They are administered in conjunction with the O2n System and Boost Goggles. The therapy is supplied in single-dose syringes for topical ophthalmic use.
Epioxa HD and Epioxa are contraindicated in patients with hypersensitivity to benzalkonium chloride or any ingredients in Epioxa HD and Epioxa. Epi-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens. In studies, the most common adverse reaction was conjunctival hyperaemia (31%).